Kaken Pharmaceutical to License Its Antifungal Compound KP-103 to Dow Pharmaceutical Sciences.

Tokyo, Japan, May 11, 2006 - (JCN JCN Japan Corporate News
JCN Journal of Cognitive Neuroscience
JCN Journal of Cardiovascular Nursing
JCN Journal of Christian Nursing
JCN Job Control Number
JCN Journal of Child Neurology
JCN joint communications network (US DoD) ) - Kaken Pharmaceutical announced on May 10 that it has concluded a licensing agreement with Dow Pharmaceutical Sciences for KP-103, Kaken Pharmaceutical's proprietary antifungal antifungal /an·ti·fun·gal/ (-fung´gal)
1. destructive to fungi, or suppressing their reproduction or growth; effective against fungal infections.

2. an agent that so acts. compound.

Going forward, Dow Pharmaceutical Sciences will develop the agent as topical preparations for mycosis mycosis: see fungal infection. including trichophytosis unguium.

Dow Pharmaceutical Sciences is a California-based company specializing in external medicine used in dermatology dermatology (dûrmətŏl`əjē), branch of medicine concerned with diagnosis and treatment of diseases and disorders of the skin. .

Copyright [c] 2006 Japan Corporate News Network. All rights reserved.

COPYRIGHT 2006 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.

Reader Opinion

Article Details
Printer friendly Cite/link Email Feedback
Publication:	JCNN News Summaries
Geographic Code:	1USA
Date:	May 11, 2006
Words:	71
Previous Article:	Eisai, Nitto Denko to Co-develop Transdermal Formulation of Alzheimer's Disease Agent ARICEPT.
Next Article:	AnGes MG Announces Results of Phase I Clinical Trial of HGF Gene Medicine.
Topics:	Pharmaceutical industry

Related Articles
Penederm signs licensing agreement with UCB subsidiary; UCB to market nail antifungal formulations in Europe and other countries.
Positive Clinical Trial Results Reported for Penederm's Antifungal Product in Athlete's Foot; Favorable Clinical Data Reported at American Academy of...
Penederm Receives "Approvable" Letter From FDA For Prescription Product to Treat Athlete's Foot.
Obesity drug takes a different strategy.(compound that increases metabolic rate may become drug to treat obesity)(Brief Article)
Penederm announces Canadian OTC approval of butenafine HCl for athlete's foot; Schering-Plough Corporation's Canadian Business Units to market.
Penederm Announces FDA Approval of Shorter Treatment Claim for Mentax; One Week Treatment for Athlete's Foot.
XECHEM/SHANGHAI FUDAN TO DEVELOP NEW PACLITAXEL ANALOGS.
Coupling agents.(Materials)
Kaken Pharmaceutical to Outsource Entire Distribution Operation to Itochu.
Kaken Pharmaceutical to License FIBLAST Wound Healing Agent to Chinese Pharmaceutical.